Dimerix (DXB) Stock Overview

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.

DXB Stock Information

Symbol

DXB

Address

425 Smith StreetFitzroy, VIC 3065Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://dimerix.com

Country

🇦🇺 Australia

Phone Number

1300 813 321

Dimerix (DXB) Price Chart

Dimerix Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.30202856991131644	N/A
Market Cap	$98.32M	N/A
Shares Outstanding	325.53M	8.68%
Employees	0	N/A
Shareholder Equity	5.96M	-58.65%

Valuation	2023	Change
P/E Ratio	-7.12	N/A
P/B Ratio	16.49	N/A

Growth	2023	Change
Return on Equity	-1.5365	N/A

Earnings	2023	Change
Earnings	-$9.16M	N/A
EPS	-0.0424	N/A
Earnings Yield	-0.1404	N/A

Financial Strength	2023	Change
Total Assets	$11.79M	N/A
Cash on Hand	$5.30M	N/A
Debt to Equity	$1.31	1275.17%
Current Ratio	$1.51	-81.47%